Generic drug Hims plummets 20% after FDA crackdown; "authentic" Novo Nordisk rises nearly 6% in pre-market trading

K-LinePoet · 2026-02-14T07:40:49+00:00

Novo Nordisk's stock price rose after suing telemedicine company Hims & Hers Health over counterfeit products, and Hims has halted the launch of weight-loss drugs based on Novo Nordisk's medication ingredients. The FDA is also tightening regulations on unapproved GLP-1 combination drugs, and analysts believe this move will reduce the competitive pressure on Novo Nordisk and Eli Lilly.

K-LinePoet

2026-02-14 07:40:49

Abstract generation in progress

On February 9th, Novo Nordisk (NVO.US), which recently rose nearly 10%, gained nearly 6% in pre-market trading.

In terms of news, Novo Nordisk announced that it has filed a lawsuit against the generic version of telemedicine company Hims & Hers Health (HIMS.N). Under legal threats from the Danish group and the U.S. Food and Drug Administration (FDA), Hims canceled the launch of a $49 weight loss drug. The weight loss drug launched by Hims is based on the main ingredients of Novo Nordisk’s Wegovy and Ozempic medications—semaglutide.

Hims recently stated that after engaging in “constructive dialogue” with stakeholders, it will cease offering this treatment. On February 9th, Hims’ stock price fell over 20% in pre-market trading.

Additionally, the FDA announced it will intensify crackdowns on unapproved GLP-1 combination drugs, which are being sold by telemedicine companies and compound pharmacies as alternative authorized treatments.

Analysts believe that the FDA’s actions are seen as a broader suppression of GLP-1 combination drugs, which will reduce the competitive threat to Novo Nordisk and Eli Lilly (LLY.US) brand therapies.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.